Skip to main content

AC Immune Stock Forecast, Price & News

+0.10 (+1.62 %)
(As of 05/12/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume131,717 shs
Average Volume729,929 shs
Market Capitalization$455.53 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ACIU News and Ratings via Email

Sign-up to receive the latest news and ratings for AC Immune and its competitors with MarketBeat's FREE daily newsletter.

AC Immune logo

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.


See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ACIU
Year FoundedN/A

Sales & Book Value

Annual Sales$111.75 million
Cash Flow$0.70 per share
Book Value$4.06 per share


Net Income$45.74 million
Net Margins-392.56%




Market Cap$455.53 million
Next Earnings Date8/4/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.31 out of 5 stars

Medical Sector

828th out of 2,045 stocks

Pharmaceutical Preparations Industry

386th out of 771 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

AC Immune (NASDAQ:ACIU) Frequently Asked Questions

Is AC Immune a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AC Immune stock.
View analyst ratings for AC Immune
or view top-rated stocks.

What stocks does MarketBeat like better than AC Immune?

Wall Street analysts have given AC Immune a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AC Immune wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is AC Immune's next earnings date?

AC Immune is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for AC Immune

How were AC Immune's earnings last quarter?

AC Immune SA (NASDAQ:ACIU) posted its earnings results on Tuesday, March, 23rd. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by $0.01. The firm earned $1.05 million during the quarter, compared to the consensus estimate of $1.27 million. AC Immune had a negative trailing twelve-month return on equity of 23.88% and a negative net margin of 392.56%.
View AC Immune's earnings history

How has AC Immune's stock price been impacted by Coronavirus?

AC Immune's stock was trading at $5.49 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ACIU shares have increased by 14.2% and is now trading at $6.27.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ACIU?

1 brokers have issued 1-year price objectives for AC Immune's stock. Their forecasts range from $16.00 to $16.00. On average, they expect AC Immune's share price to reach $16.00 in the next year. This suggests a possible upside of 155.2% from the stock's current price.
View analysts' price targets for AC Immune
or view top-rated stocks among Wall Street analysts.

Who are AC Immune's key executives?

AC Immune's management team includes the following people:
  • Dr. Andrea Pfeifer, Co-Founder, CEO & Director (Age 64, Pay $1.13M)
  • Mr. Joerg Hornstein, Chief Financial Officer (Age 43)
  • Mr. Piergiorgio Donati, Chief Technical Operations Officer (Age 50)
  • Dr. Marie Kosco-Vilbois, Chief Scientific Officer (Age 63)
  • Mr. Jean-Fabien Monin, Chief Admin. Officer (Age 50)
  • Joshua Drumm Ph.D., Head of Investor Relations
  • Mr. Alexandre Caratsch, Gen. Counsel (Age 55)
  • Judith Moore, Global Head of Communications
  • Mr. Gautam Maitra Fil. Lic, Head of Regulatory & External Affairs and Sr. Expert
  • Dr. Maria Pihlgren Ph.D., Head of Biology

What is Andrea Pfeifer's approval rating as AC Immune's CEO?

3 employees have rated AC Immune CEO Andrea Pfeifer on Andrea Pfeifer has an approval rating of 35% among AC Immune's employees. This puts Andrea Pfeifer in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of AC Immune's key competitors?

What other stocks do shareholders of AC Immune own?

When did AC Immune IPO?

(ACIU) raised $55 million in an initial public offering (IPO) on Friday, September 23rd 2016. The company issued 4,600,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.

What is AC Immune's stock symbol?

AC Immune trades on the NASDAQ under the ticker symbol "ACIU."

Who are AC Immune's major shareholders?

AC Immune's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (0.86%), Acadian Asset Management LLC (0.38%), Compagnie Lombard Odier SCmA (0.31%), Banque Cantonale Vaudoise (0.10%) and Geode Capital Management LLC (0.05%).

Which major investors are selling AC Immune stock?

ACIU stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, and BlackRock Inc..

Which major investors are buying AC Immune stock?

ACIU stock was purchased by a variety of institutional investors in the last quarter, including Compagnie Lombard Odier SCmA, Banque Cantonale Vaudoise, and Geode Capital Management LLC.

How do I buy shares of AC Immune?

Shares of ACIU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AC Immune's stock price today?

One share of ACIU stock can currently be purchased for approximately $6.27.

How much money does AC Immune make?

AC Immune has a market capitalization of $455.53 million and generates $111.75 million in revenue each year. The company earns $45.74 million in net income (profit) each year or $0.60 on an earnings per share basis.

How many employees does AC Immune have?

AC Immune employs 125 workers across the globe.

What is AC Immune's official website?

The official website for AC Immune is

Where are AC Immune's headquarters?

AC Immune is headquartered at EPFL Innovation Park Building B, Lausanne V8, 1015.

How can I contact AC Immune?

AC Immune's mailing address is EPFL Innovation Park Building B, Lausanne V8, 1015. The company can be reached via phone at 41-21-345-9121 or via email at [email protected]

This page was last updated on 5/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.